The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications.

By E. Dejana, E. Tournier-Lasserve, B. Weinstein. Developmental Cell, 2009

793 citations recorded by the source corpus.

Subfields: Cell Biology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/d9f3ab01093a2bd37b9be4a8b1001764541a0de7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

In Molecular Biology

Citations in the corpus

Dengue Virus Pathogenesis: an Integrated View (2009, background): “The pathogenesis of mild hemorrhages seen in DF and DHF grades I/II may be explained by increased capillary fragility as a result of thrombocytopenia or platelet dysfunction, virus infection of EC, and high concentrations of cytokines that disrupt vascular integrity (54, 170, 257).”
The lymphatic vasculature in disease (2011, background): “Instead of the zipper-like endothelial junctions that occur between BECs, LECs have discontinuous button-like junctions, allowing fluid and certain leukocytes to enter into the vessel lumen through flap-like openings that form the primary lymphatic valve”
The blood–brain and the blood–cerebrospinal fluid barriers: function and dysfunction (2009, background): “In vascular beds outside of the CNS, endothelial adherens junctions have been demonstrated to be important regulators of vascular permeability (reviewed in [23]), while at the BBB they have been considered less relevant in regulating BBB paracellular permeability [24].”
Molecular mechanisms and clinical applications of angiogenesis (2011, background): “The tight junctional molecules claudins, occludins and junctional adhesion molecules maintain barriers, such as the BBB, whereas adherens junctions establish cell–cell adhesion, cytoskeleton remodelling and intracellular signallin”
Tumor angiogenesis and vascular normalization: alternative therapeutic targets (2017, background): “Tumor cells release proteolytic enzymes as MMPs, elastase or trypsin to promote VEcadherin cleavage [31].”